Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer
- 604 Downloads
While intact circulating tumor cells (iCTC) have independent negative prognostic impact on patients with metastatic breast cancer (MBC), the prognostic relevance of apoptotic CTC (aCTC) has not been validated in larger patient cohorts. This study assessed aCTC and iCTC statuses at baseline (CTCBL) and CTC kinetics (CTCKIN) as changes from CTCBL to one completed treatment cycle for their utility in predicting response, progression-free survival (PFS), and overall survival (OS) in MBC.
Status of iCTC and aCTC was prospectively assessed in 442 patients using the CellSearch™ system. Different cutoffs were analyzed both for iCTC and aCTC (≥5, ≥10, ≥25 and ≥50 CTC/7.5 ml). CTCKIN were characterized by ≥25 % changes in CTC counts.
Numbers of iCTC and aCTC at baseline correlated strongly (r = 0.7). For iCTCBL positive patients, additional detection of aCTCBL had a significant prognostic impact on OS (aCTCBL positive 10.3 vs. aCTCBL negative 16.4 months, p = 0.012). Worst prognosis for OS was observed in patients with ≥50 iCTC/7.5 ml and simultaneously detected aCTC. Determination of aCTCKIN showed stronger discriminating power than iCTCKIN, with higher PFS and OS for the group with decreasing CTCs (PFS 7.7 vs. 6.1; OS 22.2 vs. 16.4).
Intact and aCTC are predictive of outcome in MBC. Apoptotic CTC counts ≥ 5/7.5 ml in conjunction with iCTC at baseline have an independent unfavorable prognostic impact on OS. Decreasing aCTCKIN at ≥ 5/7.5 ml in serial enumeration is associated with favorable outcome. Therefore, separate enumeration of iCTC and aCTC is useful in tailoring systemic treatment.
KeywordsMetastatic breast cancer Circulating tumor cell Apoptotic circulating tumor cell Treatment response Kinetic Survival
One cycle of systemic chemotherapy
Apoptotic circulating tumor cell(s)
Circulating tumor cell(s)
Disseminated tumor cell(s)
Epithelial cell adhesion molecule
Intact circulating tumor cell(s)
Metastatic breast cancer
Not available/not applicable
National Center for Tumor Diseases, Heidelberg, Germany
Neoadjuvant systemic therapy
The authors gratefully acknowledge all patients whose data were used in this study. We also thank the medical and nursing staff, especially Martina Scharpff, at the National Center for Tumor Diseases (NCT; Heidelberg) for excellent management and care of our patients; the NCT laboratory staff; and Antje Andreas; Cornelia Coith; and Oliver Mauermann (Hamburg), who provided excellent technical assistance with the CTC determinations. This study was supported by NCT in-house funds, made available to AS and AT, and by grants to AT from the BioRN Leading Edge Cluster “Molecular and Cell Based Medicine” (BRN 02GS1893), supported by the German Federal Ministry of Education and Research (BMBF), Berlin, Germany (BMBF N02/74829), and the Dietmar Hopp Foundation. Moreover, this study was supported by the ERC-2010-AdG_20100317 DISSECT to KP. We acknowledge the financial support from the German Research Foundation (DFG) and Ruprecht-Karls-Universität Heidelberg through the funding program for Open Access Publishing.
MW, ADH, SR, KP, AT, and AS jointly conceived the study and developed its design. MW and AS supervised the study. SR and KP developed the methodology. TMD, SR, JN, ADH, MRS, BS, CS, KP, AT, AS, and MW participated in patient recruitment, patient management, clinical data collection, sample collection, and sample analysis. BS and TMD organized and reported the data, constructed the databases, and conducted data management. BS performed the statistical analysis. TMD, JN, ADH, SS, SYB, SR, FS, CD, MRS, BS, CS, AT, AS, and MW participated in data analysis and interpretation. TMD, JN, ADH, BS, AS, and MW drafted the manuscript. MW, SR, MRS, CS, KP, SR, SS, TMD, ADH, BS, SYB, AS, and AT revised the draft manuscript for important intellectual input. MW prepared the final manuscript. All the authors read and approved the final manuscript.
Compliance with ethical standards
The authors declare that they have no competing interests.
- 2.Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH et al (2012) Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 11(11):2526–2534CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Wallwiener M, Riethdorf S, Hartkopf AD, Modugno C, Nees J, Madhavan D, Sprick MR, Schott S, Domschke C, Baccelli I et al (2014) Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 14:512CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(14 Pt 1):4218–4224CrossRefPubMedGoogle Scholar
- 5.Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M et al (2011) Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544CrossRefPubMedGoogle Scholar
- 13.Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11(4):R59CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schonfisch B, Taran FA, Heil J, Sohn C, Pantel K et al (2015) The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer 15:403CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S et al (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 16(21):5233–5243CrossRefPubMedGoogle Scholar
- 19.Russo A, Terrasi M, Agnese V, Santini D, Bazan V (2006) Apoptosis: a relevant tool for anticancer therapy. Ann Oncol 17(Suppl 7 vii):115–123Google Scholar
- 21.Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Durr-Storzer S, Neubauer H, Wallwiener D, Solomayer EF (2006) Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 8(5):R60CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Hartkopf AD, Taran FA, Wallwiener M, Hagenbeck C, Melcher C, Krawczyk N, Hahn M, Wallwiener D, Fehm T (2013) The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy. Breast Cancer Res 15(5):R94CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I et al (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634–2645CrossRefPubMedGoogle Scholar
- 24.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMedGoogle Scholar
- 27.R: A Language and environment for statistical computing. http://www.r-project.org
- 30.Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Lohberg CR, Solomayer E, Rack B et al (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124(2):403–412CrossRefPubMedGoogle Scholar